Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand–foot skin reactions

  • Short Communication
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

The purpose of this study is to evaluate the efficacy of a protocol including topical heparin therapy for hand–foot skin reactions (HFSR) during multikinase (MKI) treatment.

Methods

We prospectively collected 26 patients who had HFSRs during treatment with the MKIs, sunitinib, sorafenib, or axitinib. The age distribution ranged from 46 to 87 years, with a mean of 66 years. The distribution of HFSR severity was 12 patients with grade 1, 12 with grade 2, and 2 with grade 3. A heparin-containing topical ointment treatment, combined with hand–foot shock absorbers and skin moisturizers, was used at the lesion sites. Changes in the grade of HFSR, MKI dosage, and interruptions of MKI therapy were recorded.

Results

The results showed that 66.7 % of grade 1 patients were cured of disease, 83.3 % of grade 2 patients had improved symptoms, and both grade 3 patients (100 %) had improved symptoms and were downgraded to grade 2. Four (15.4 %) patients required reduction of MKI dosage, but there were no treatment interruptions or dropouts.

Conclusion

Our protocol is beneficial in promoting resolution of HFSRs induced by MKIs. Further validation in large control studies should be investigated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124

    Article  PubMed  CAS  Google Scholar 

  2. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007(356):125–134

    Article  Google Scholar 

  3. Rini BI, Wilding G, Hudes G et al (2009) Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4462–4468

    Article  PubMed  CAS  Google Scholar 

  4. Tsai KY, Yang CH, Kuo TT, Hong HS, Chang JW (2006) Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 24:5786–5788

    Article  PubMed  Google Scholar 

  5. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ (2008) Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 13:1084–1096

    Article  PubMed  CAS  Google Scholar 

  6. Bhojani N, Jeldres C, Patard JJ et al (2008) Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53:917–930

    Article  PubMed  CAS  Google Scholar 

  7. Tomita Y, Shinohara N, Yuasa T et al (2010) Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 40:1166–1172

    Article  PubMed  Google Scholar 

  8. Zhang H, Dong B, Lu JJ et al (2009) Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study. BMC Cancer 9:249

    Article  PubMed  Google Scholar 

  9. Lee WJ, Lee JL, Chang SE et al (2009) Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 161:1045–1051

    Article  PubMed  CAS  Google Scholar 

  10. Di Lorenzo G, Porta C, Bellmunt J et al (2011) Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 59:526–540

    Article  PubMed  Google Scholar 

  11. Schmidinger M, Arnold D, Szczylik C, Wagstaff J, Ravaud A (2010) Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. Cancer Invest 28:856–864

    Article  PubMed  CAS  Google Scholar 

  12. Manchen E, Robert C, Porta C (2011) Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. J Support Oncol 9:13–23

    Article  PubMed  CAS  Google Scholar 

  13. Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434

    Article  PubMed  CAS  Google Scholar 

  14. Peplow PV (2005) Glycosaminoglycan: a candidate to stimulate the repair of chronic wounds. Thromb Haemost 94:4–16

    PubMed  CAS  Google Scholar 

  15. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

    Article  PubMed  CAS  Google Scholar 

  16. Di Lorenzo G, Autorino R, Sternberg CN (2009) Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur Urol 56:959–971

    Article  PubMed  Google Scholar 

  17. Rini BI (2009) Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol 27:3225–3234

    Article  PubMed  CAS  Google Scholar 

  18. Saylor PJ, Michaelson MD (2009) New treatments for renal cell carcinoma: targeted therapies. J Natl Compr Canc Netw 7:645–656

    PubMed  CAS  Google Scholar 

  19. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34

    Article  PubMed  CAS  Google Scholar 

  20. Chu D, Lacouture ME, Weiner E, Wu S (2009) Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 7:11–19

    Article  PubMed  Google Scholar 

  21. Escudier B, Szczylik C, Hutson TE et al (2009) Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1280–1289

    Article  PubMed  CAS  Google Scholar 

  22. Yang CH, Lin WC, Chuang CK et al (2008) Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 158:592–596

    Article  PubMed  CAS  Google Scholar 

  23. Oremus M, Hanson MD, Whitlock R et al (2007) A systematic review of heparin to treat burn injury. J Burn Care Res 28:794–804

    Article  PubMed  Google Scholar 

Download references

Conflict of Interest

The authors report no conflict of interest. The authors alone are responsible for the content and writing of the paper. The authors have full control over all primary data and agree to allow the journal review data if requested.

Author information

Authors and Affiliations

  1. Division of Urology, Department of Surgery, Taichung Veterans General Hospital, 160, Section 3, Taichung-Kung Rd., Taichung, 407, Taiwan, , Republic of China

    Jian-ri Li, Chen-li Cheng, Hao-chung Ho, Kun-yuan Chiu, Chung-Kuang Su, Wen-Ming Chen, Shian-Shiang Wang, Chuan-Shu Chen, Cheng-Kuang Yang & Yen-chuan Ou

  2. Department of Urology, China Medical University Hospital, Taichung, Taiwan, Republic of China

    Chi-rei Yang

  3. Institute of Medical and Molecular Toxicology, Chung Shan Medical University, Taichung, Taiwan, Republic of China

    Jian-ri Li

Authors
  1. Jian-ri Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chi-rei Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chen-li Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hao-chung Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kun-yuan Chiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chung-Kuang Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wen-Ming Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shian-Shiang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chuan-Shu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Cheng-Kuang Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yen-chuan Ou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yen-chuan Ou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, Jr., Yang, Cr., Cheng, Cl. et al. Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand–foot skin reactions. Support Care Cancer 21, 907–911 (2013). https://doi.org/10.1007/s00520-012-1693-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-012-1693-3

Keywords

Search

Navigation